These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36648390)

  • 1. Adequacy of cefepime concentrations in the early phase of critical illness: A case for precision pharmacotherapy.
    Barreto EF; Chang J; Bjergum MW; Gajic O; Jannetto PJ; Mara KC; Meade LA; Rule AD; Vollmer KJ; Scheetz MH;
    Pharmacotherapy; 2023 Nov; 43(11):1112-1120. PubMed ID: 36648390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic model of cefepime for critically ill adults: a comparative assessment of eGFR equations.
    Barreto EF; Chang J; Rule AD; Mara KC; Meade LA; Paul J; Jannetto PJ; Athreya AP; Scheetz MH;
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0081023. PubMed ID: 37882514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefepime pharmacokinetics in critically ill children and young adults undergoing continuous kidney replacement therapy.
    Pavia K; Hambrick HR; Paice K; Tang P; Punt N; Kaplan J; Goldstein SL; Vinks AA; Mizuno T; Tang Girdwood S
    J Antimicrob Chemother; 2023 Sep; 78(9):2140-2147. PubMed ID: 37466170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefepime population pharmacokinetics and dosing regimen optimization in critically ill children with different renal function.
    de Cacqueray N; Hirt D; Zheng Y; Bille E; Leger PL; Rambaud J; Toubiana J; Chosidow A; Vimont S; Callot D; Chouchana L; Béranger A; Tréluyer JM; Benaboud S; Oualha M
    Clin Microbiol Infect; 2022 Oct; 28(10):1389.e1-1389.e7. PubMed ID: 35605841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Population Pharmacokinetic Analysis to Study the Effect of Extracorporeal Membrane Oxygenation on Cefepime Disposition in Children.
    Zuppa AF; Zane NR; Moorthy G; Dalton HJ; Abraham A; Reeder RW; Carcillo JA; Yates AR; Meert KL; Berg RA; Sapru A; Mourani P; Notterman DA; Dean JM; Gastonguay MR;
    Pediatr Crit Care Med; 2019 Jan; 20(1):62-70. PubMed ID: 30431557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Cefepime in Children on Extracorporeal Membrane Oxygenation: External Model Validation, Model Improvement and Dose Optimization.
    Thibault C; Moorthy GS; Vedar C; Naim MY; DiLiberto MA; Zuppa AF
    Pediatr Infect Dis J; 2022 Mar; 41(3):217-223. PubMed ID: 34817416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study).
    Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Corley A; Diehl A; Jakob SM; Levkovich BJ; Pellegrino V; Que YA; Reynolds C; Rudham S; Wallis SC; Welch SA; Zacharias D; Roberts JA; Shekar K; Fraser JF
    Int J Antimicrob Agents; 2021 Dec; 58(6):106466. PubMed ID: 34688834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO).
    Kois AK; Gluck JA; Nicolau DP; Kuti JL
    Int J Antimicrob Agents; 2022 Jul; 60(1):106603. PubMed ID: 35577257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.
    Crandon JL; Bulik CC; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1111-6. PubMed ID: 20038614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing.
    Al-Shaer MH; Neely MN; Liu J; Cherabuddi K; Venugopalan V; Rhodes NJ; Klinker K; Scheetz MH; Peloquin CA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients.
    Bilal M; Zoller M; Fuhr U; Jaehde U; Ullah S; Liebchen U; Büsker S; Zander J; Babouee Flury B; Taubert M
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0030923. PubMed ID: 37366614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation.
    Kim YK; Kim HS; Park S; Kim HI; Lee SH; Lee DH
    J Antimicrob Chemother; 2022 Apr; 77(5):1353-1364. PubMed ID: 35224630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefepime Pharmacokinetics in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy.
    Stitt G; Morris J; Schmees L; Angelo J; Akcan Arikan A
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients.
    An G; Creech CB; Wu N; Nation RL; Gu K; Nalbant D; Jimenez-Truque N; Fissell W; Patel PC; Fishbane N; Watanabe A; Rolsma S; Kirkpatrick CMJ; Landersdorfer CB; Winokur P
    J Antimicrob Chemother; 2023 Jun; 78(6):1460-1470. PubMed ID: 37071586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
    Taccone FS; Laterre PF; Dugernier T; Spapen H; Delattre I; Wittebole X; De Backer D; Layeux B; Wallemacq P; Vincent JL; Jacobs F
    Crit Care; 2010; 14(4):R126. PubMed ID: 20594297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Al-Shaer MH; Philpott CD; Droege CA; Courter JD; Healy DP; Droege ME; Ernst NE; Mueller EW; Peloquin CA
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
    Al-Shaer MH; Maguigan K; Ashton J; Venugopalan V; Droege ME; Philpott CD; Droege CA; Healy DP; Mueller EW; Peloquin CA
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0161121. PubMed ID: 34662194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.